tradingkey.logo
tradingkey.logo

Bristol-Myers Squibb Says Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfy

ReutersMar 28, 2026 11:13 AM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL-MYERS SQUIBB: OPEN LABEL OUTPATIENT SWITCH STUDY DEMONSTRATES SYMPTOM STABILITY DURING TRANSITION FROM ORAL ATYPICAL ANTIPSYCHOTICS TO COBENFY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI